1. Three people have died from meningococcal disease this year in NSW, two were aged 15-25 years 2. Recent fatal cases had rapid onset with fever, nausea, and vomiting predominating 3. Early identification and rapid treatment can save lives 4. Cases this year are due to serogroup B 5. MenACWY vaccine and MenB vaccine is recommended to anyone who wants to protect against disease.
Meningococcal disease cases are above average for the time of year. All cases in 2022 (29) have been due to serogroup B, three cases have died. A recent cluster of 4 cases, including two deaths, have been in the Illawarra Shoalhaven area. Children 0-4 years and people aged 15-25 years are at highest risk of IMD.
Invasive Meningococcal Disease
IMD is caused by several serogroups of Neisseria meningitidis. Serogroups B, C, W and Y have caused the majority of IMD in Australia. Recent cases have predominately been caused by serogroup B.
IMD is a rare but serious disease. Historically up to 10% of cases have been fatal even with appropriate antibiotic treatment. Survivors are often left with long-term sequelae.
Symptoms of invasive Meningococcal Disease
Early meningococcal disease symptoms can be non-specific and mimic other common illnesses like respiratory or gastro viruses. Onset is often sudden, and illness progresses rapidly.
As soon as a clinician suspects meningitis clinically administer an immediate dose of ceftriaxone or benzylpenicillin and urgently transfer to an ED if not already there. Please refer to Guidelines
Symptoms may include sudden onset of fever, severe headache, neck stiffness, unexplained joint, limb or abdominal pain, a non-blanching rash of red-purple spots or bruises, photophobia, nausea, and vomiting. Symptoms in young children include irritability, difficulty waking, high-pitched crying, and refusal to eat.
The ‘meningococcal rash’ does not always appear, and often occurs late in the illness.
Patients should always be advised to urgently re-attend if symptoms rapidly progress or worsen.
Any person who wants to protect themselves against invasive meningococcal disease can receive MenACWY and MenB vaccines from as early as 6 weeks of age.
The National Immunisation Program (NIP) includes meningococcal vaccination for certain groups and meningococcal vaccines are also available via private prescription. GPs and now pharmacists are now also able to administer meningococcal vaccines for people aged 5 years and over. As vaccine schedules and serogroups covered have changed over time, history of vaccination should not exclude a diagnosis of IMD.
Groups eligible for free vaccine
Meningococcal ACWY vaccine A
All children at 12 months of age Children aged 15-19 years*
Meningococcal B vaccine
Aboriginal children < 2 years of age
People with certain medical conditions that cause increased risk of infection^
*via the school vaccination program, their GP, or registered pharmacist immunisers ^including asplenia, hyposplenia, complement deficiency and those receiving eculizumab treatment
Public Health Response and further information:
Outbreaks of IMD can occur and it is important to urgently notify your Public Health Unit on 1300 066 055 of any suspected case to facilitate management of close contacts and prevent further cases.
Welcome to our new website! As you may have noticed, our website looks different. Central and Eastern Sydney PHN have moved to a new site and although much has remained the same, we have introduced some new functions. These include: Updated navigation When you land on our new website, you…
Immunisation weekly update – 1 February 2023 Childhood immunisation overdue reports CESPHN is inviting general practices to sign up to receive a regular report extracted on your behalf from the Australian Immunisation Register (AIR) which is specific to your practice. This report contains all children aged 0-5 living in the CESPHN region…
Australian Digital Health Agency (ADHA) digital health webinars Implementing MyHealth Record Policies in your organisation Thu 9 Feb 23, 12.30-1.00 pm – learn how to implement and maintain a My Health Record Security and Access policy in your organisation. Understand the importance of the Responsible Officer (RO) and Organisational Maintenance…
UNSW research – Palliative care and intellectual disability A research team led by Professor Julian Trollor at the Department of Developmental Disability Neuropsychiatry, UNSW Sydney, aims to design, implement, and evaluate a new palliative care service for people with intellectual disability. This is important because people with intellectual disability often…
GP support needed: Shared e-Care plan study for follow-up of colorectal and breast cancers This research evaluates shared care using a new interactive e-care plan being implemented through cancer services in Prince of Wales and St George public and private hospitals. Through the e-care plan GPs, cancer specialists and patients…
Seeking GP insight for HealthPathways Sydney improvement project Since its launch in March 2014, the HealthPathways Sydney program has developed nearly one thousand clinical HealthPathways and referral resources. The HealthPathways Sydney team are currently investigating how to make our processes for reviewing and updating content more efficient; ensuring that pathway…
Future of Home & Community Care Hybrid Conference The new Support at Home program and broader sector-wide reforms will have a significant impact on the way that Home and Community Care services are delivered and funded. You may have many questions over what the final model will look like, and…